Purpose: To investigate the effects of sildenafil, a popular new drug in the t reatment of erectile dysfunction, on ocular blood flow. Methods: This study was designed as a prosp ective, double-blind, placebo-controll...Purpose: To investigate the effects of sildenafil, a popular new drug in the t reatment of erectile dysfunction, on ocular blood flow. Methods: This study was designed as a prosp ective, double-blind, placebo-controlled study. Twenty participants with ere ctile dysfunction were given a single oral dose of 100 mg sildenafil, while 10 p articipants with erectile dysfunction were given placebo. All the participants u nderwent routine systemic and ophthalmological examinations. Intraocular pressur e, systolic and diastolic blood pressure and ocular blood flow (ophthalmic, cent ral retinal, short posterior ciliary arteries) were measured in both eyes before and 1 hour after the dose of sildenafil or placebo. Ocular blood flow measureme nts were performed using colour Doppler ultrasonography. Results: None of the pa rameters were significantly different between the groups before study drug intak e. Although central retinal artery velocitieswere not changed,ophthalmic artery and short posterior ciliary artery peak systolic velocity,end-diastolic velocit y, and mean velocity values were significantly increased 1 hour after drug intak e in the sildenafil group compared to the placebo group (p < 0.05). Conclusion: Sildenafil causes a significant increase in blood flow in these arteries. A poss ible role of inhibition of phosphodiesterase-5 in vascular smooth muscles by si ldenafil is implicated. Further studies are needed to investigate the effects of sildenafil on ocular blood flow in patients with senile macular degeneration, d iabetic retinopathy and glaucoma.展开更多
文摘Purpose: To investigate the effects of sildenafil, a popular new drug in the t reatment of erectile dysfunction, on ocular blood flow. Methods: This study was designed as a prosp ective, double-blind, placebo-controlled study. Twenty participants with ere ctile dysfunction were given a single oral dose of 100 mg sildenafil, while 10 p articipants with erectile dysfunction were given placebo. All the participants u nderwent routine systemic and ophthalmological examinations. Intraocular pressur e, systolic and diastolic blood pressure and ocular blood flow (ophthalmic, cent ral retinal, short posterior ciliary arteries) were measured in both eyes before and 1 hour after the dose of sildenafil or placebo. Ocular blood flow measureme nts were performed using colour Doppler ultrasonography. Results: None of the pa rameters were significantly different between the groups before study drug intak e. Although central retinal artery velocitieswere not changed,ophthalmic artery and short posterior ciliary artery peak systolic velocity,end-diastolic velocit y, and mean velocity values were significantly increased 1 hour after drug intak e in the sildenafil group compared to the placebo group (p < 0.05). Conclusion: Sildenafil causes a significant increase in blood flow in these arteries. A poss ible role of inhibition of phosphodiesterase-5 in vascular smooth muscles by si ldenafil is implicated. Further studies are needed to investigate the effects of sildenafil on ocular blood flow in patients with senile macular degeneration, d iabetic retinopathy and glaucoma.
